Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,7 +2,7 @@
2	2	{{toc/}}
3	3	{{/box}}
4	4
5		-= Paragraph 1 =
	5	+= =
6	6
7	7	Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
8	8
...	...	@@ -10,7 +10,7 @@
10	10
11	11	The Company was incorporated on October 31, 2011. The Company is engaged in the application stage of producing medical marijuana at its facility located in Delta, British Columbia and developing turnkey indoor production facilities for approved marijuana license holders in State of Washington. The Company is currently active in Canada and the United States. The Company is a reporting issuer in British Columbia and Ontario, and trades on the CSE under the symbol “VP” and the Frankfort Stock Exchange under the symbol “1JV”.
12	12
13		-==== Corporate Highlights: ====
	13	+= Corporate Highlights: =
14	14
15	15	* Vodis’ wholly owned US subsidiary “Vodis USA” completed licensing of its phase two expansion at the Bellingham facility. This latest build out which is approximately 75% complete will bring available tenant utilization to 55% of the permitted 10,000 square foot Tier 2 canopy capacity.
16	16	* Vodis USA signed a 15-year licensing agreement whereby the Vodis name, image and various Vodisinspired designs and concepts will be used to brand, market, and sell marijuana products across Washington State through a product licensing and marketing agreement with a Washington State marijuana licensee, Premium Cannabis Producers ("PCP) (formerly, The company's Church International LLC). The compensation schedule, based on gross aggregate sales, ranges from US$0.34 to US$0.40 per dollar of Vodis branded product sold by PCP.
...	...	@@ -43,12 +43,14 @@
43	43
44	44	The Company is party to a sublease agreement with PCP, licensed Tier 2 tenant, (the “Tenant”) to sublet the property leased by Vodis USA under the Master Lease. The lease with the Tenant expires on the earlier of one day prior to the termination of the Master Lease if the Company does not exercise the option to purchase the investment property by April 30, 2035
45	45
46		-==== Future plans ====
	46	+= Future plans =
47	47
48	48	The Company intends to leverage its expertise in building out a successful revenue model in the State of Washington and use similar approaches in other states that are regulating and legalizing medical or recreational marijuana use. The Company has started undertaking discussions with interested partners in other states.
49	49
50		-==== Recent updates ====
	50	+= Recent updates =
51	51
52	52	On December 20, 2017, Vodis Pharmaceuticals Inc. announces the appointment of John Bean as a director of the Company effective immediately.
53	53
54	54	On December 15, 2017, Vodis Pharmaceuticals Inc. announced the closing of a non-brokered private placement of 8,060,000 units (each, an “Offered Unit") at a price of $0.25 per Offered Unit (the “Offering”) for gross proceeds of $2,015,000. The proceeds from the Offering will be used to complete the expansion of the Company’s facility in Bellingham, Washington, and the process of upgrading its Delta, BC, location, and for general working capital and corporate purposes.
	55	+
	56	+= References =